Weiss Richard, Scheiblhofer Sandra, Thalhamer Josef
Department of Molecular Biology; University of Salzburg; Salzburg, Austria.
Hum Vaccin Immunother. 2014;10(3):703-7. doi: 10.4161/hv.27183. Epub 2013 Nov 26.
Vaccination against infectious diseases has been one of the major breakthroughs in human medical history, saving the lives of millions of people each year. More recently, prophylactic vaccination against non-infectious diseases such as cancer, Alzheimer's disease, diabetes, and type I allergy is being investigated. Particularly in case of IgE-driven allergic disorders, which afflict almost a quarter of the population in highly developed countries, preventative measures would represent a major improvement for patients' health as well as an economic relief for public health services. As an alternative to allergen-specific immunotherapy, prophylactic vaccination against type I allergic diseases could slow down or even stop the progress of the allergy pandemic. Allergen-encoding gene-based vaccines, i.e., plasmid DNA and mRNA vaccines, provide the advantage of purity over crude allergen extracts, which involve the risk of de novo sensitizations. Furthermore, these formulations have been demonstrated to induce T helper 1 as well as T regulatory immune responses--a pre-requisite for prophylactic intervention against allergies. However, prophylactic vaccines against environmental allergens strikingly differ from conventional vaccines against infectious diseases or therapeutic approaches concerning the underlying immunological mechanisms.
针对传染病的疫苗接种一直是人类医学史上的重大突破之一,每年挽救数百万人的生命。最近,人们正在研究针对癌症、阿尔茨海默病、糖尿病和I型过敏等非传染性疾病的预防性疫苗接种。特别是在由IgE驱动的过敏性疾病方面,在高度发达国家几乎影响四分之一的人口,预防措施将对患者健康有重大改善,同时也为公共卫生服务减轻经济负担。作为变应原特异性免疫疗法的替代方法,针对I型过敏性疾病的预防性疫苗接种可以减缓甚至阻止过敏大流行的进程。基于变应原编码基因的疫苗,即质粒DNA疫苗和mRNA疫苗,比粗制变应原提取物具有纯度优势,粗制变应原提取物存在引发新致敏的风险。此外,这些制剂已被证明可诱导辅助性T细胞1以及调节性T细胞免疫反应,这是针对过敏进行预防性干预的先决条件。然而,针对环境变应原的预防性疫苗与针对传染病的传统疫苗或治疗方法在潜在免疫机制方面存在显著差异。